Want to see JP:4931 full AI Analyst Report?
Top Page
Shinnihonseiyaku Co., Ltd.
(4931)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥2,211.00
▼(-0.94% Downside)
Action:Upgraded
Date:08/04/26
The score is primarily supported by strong financial stability (minimal leverage) and solid cash flow efficiency, partially offset by weakening growth and some profitability pressure. Technical signals are mixed/neutral, while valuation appears reasonable with a moderate P/E and a 2.57% dividend yield.
Positive Factors
Balance sheet strength
Extremely low leverage (debt-to-equity ~0.003) provides durable financial resilience and strategic optionality. Minimal interest burden and a strong equity base support stable dividends, targeted brand investment and potential M&A or capex without stressing liquidity in a downturn.
Negative Factors
Negative revenue growth
A -7.3% revenue decline is a material structural concern: shrinking top line reduces economies of scale, limits marketing and R&D budgets, and makes sustaining brand momentum harder. If revenue erosion persists, long-term growth and market position could be impaired.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low leverage (debt-to-equity ~0.003) provides durable financial resilience and strategic optionality. Minimal interest burden and a strong equity base support stable dividends, targeted brand investment and potential M&A or capex without stressing liquidity in a downturn.
Read all positive factors
Shinnihonseiyaku Co., Ltd. (4931) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥45.10B
Dividend Yield2.47%
Average Volume (3M)55.11K
Price to Earnings (P/E)13.5
Beta (1Y)0.35
Revenue Growth3.38%
EPS Growth32.41%
CountryJP
Employees316
SectorConsumer Cyclical
Sector Strength84
IndustrySpecialty Retail
Share Statistics
EPS (TTM)155.54
Shares Outstanding21,855,200
10 Day Avg. Volume51,180
30 Day Avg. Volume55,106
Financial Highlights & Ratios
PEG Ratio-2.68
Price to Book (P/B)2.13
Price to Sales (P/S)1.18
P/FCF Ratio10.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)160.5
Revenue Forecast (FY)¥43.70B
Shinnihonseiyaku Co., Ltd. Business Overview & Revenue Model
Company Description
Shinnihonseiyaku Co., Ltd. is a Japanese-headquartered company, established in 1992, that specializes in providing cosmetics, pharmaceuticals, and health foods both domestically and in international markets. The company's operations are structured...
How the Company Makes Money
Shinnihonseiyaku makes money primarily by selling its own branded healthcare/consumer health products (e.g., supplements and related health-oriented consumer goods) and recognizing revenue when these products are delivered/sold through its sales c...
Shinnihonseiyaku Co., Ltd. Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
85
Very Positive
Cash Flow
75
Positive
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.56B | 41.14B | 40.04B | 37.65B | 36.11B | 33.90B |
| Gross Profit | 33.55B | 32.58B | 31.53B | 29.98B | 29.07B | 28.08B |
| EBITDA | 4.96B | 5.15B | 4.49B | 4.19B | 3.95B | 3.85B |
| Net Income | 3.29B | 2.55B | 2.79B | 2.39B | 2.36B | 2.32B |
Balance Sheet | ||||||
| Total Assets | 29.03B | 28.44B | 27.28B | 25.50B | 23.86B | 23.24B |
| Cash, Cash Equivalents and Short-Term Investments | 18.59B | 18.12B | 16.34B | 15.52B | 14.35B | 13.65B |
| Total Debt | 349.00M | 76.00M | 253.00M | 446.00M | 1.84B | 2.24B |
| Total Liabilities | 4.79B | 5.63B | 5.48B | 5.84B | 5.94B | 7.06B |
| Stockholders Equity | 24.24B | 22.81B | 21.79B | 19.66B | 17.92B | 16.18B |
Cash Flow | ||||||
| Free Cash Flow | 4.63B | 4.63B | 1.93B | 3.37B | 2.25B | 1.97B |
| Operating Cash Flow | 4.69B | 4.69B | 2.10B | 3.47B | 2.29B | 2.07B |
| Investing Cash Flow | -1.79B | -1.79B | -382.00M | -208.00M | -496.00M | -1.36B |
| Financing Cash Flow | -2.10B | -2.10B | -902.00M | -2.10B | -1.09B | 672.00M |
Shinnihonseiyaku Co., Ltd. Technical Analysis
Positive
2232.00
Price Trends
2017.38
Positive
1998.46
Positive
2031.85
Positive
Market Momentum
24.34
Negative
64.48
Neutral
82.62
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4931, the sentiment is Positive. The current price of 2232 is above the 20-day moving average (MA) of 2047.20, above the 50-day MA of 2017.38, and above the 200-day MA of 2031.85, indicating a bullish trend. The MACD of 24.34 indicates Negative momentum. The RSI at 64.48 is Neutral, neither overbought nor oversold. The STOCH value of 82.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4931.
Shinnihonseiyaku Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥45.10B | 13.55 | ― | 2.53% | 3.38% | 32.41% | |
66 Neutral | ¥57.24B | -85.27 | ― | ― | ― | ― | |
64 Neutral | ¥519.31B | 16.14 | ― | 1.28% | 8.72% | 3.45% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
61 Neutral | ¥32.97B | 8.31 | ― | 1.29% | 8.85% | -9.80% | |
59 Neutral | ¥5.87B | 49.80 | ― | 2.65% | 9.45% | ― | |
38 Underperform | ¥5.72B | -3.69 | ― | ― | ― | 33.26% |
* Consumer Cyclical Sector Average
JP:4931
Shinnihonseiyaku Co., Ltd.
2,107.00
-231.52
-9.90%
JP:2796
Pharmarise Holdings Corp.
500.00
10.19
2.08%
JP:3349
COSMOS Pharmaceutical Corporation
6,524.00
-2,190.66
-25.14%
JP:7679
Yakuodo Holdings Co., Ltd.
1,670.00
-575.18
-25.62%
JP:190A
Chordia Therapeutics Inc.
74.00
-106.00
-58.89%
JP:219A
Heartseed, Inc.
2,500.00
-1,090.00
-30.36%
Shinnihonseiyaku Co., Ltd. Corporate Events
Shinnihonseiyaku Hits Record Q3 Sales as Healthcare Surges Amid Strategic Brand Investment
Aug 7, 2026
Shinnihonseiyaku reported Q3 net sales of ¥11,635 million, an all-time quarterly high, contributing to ¥32,153 million in sales for the first nine months, up 4.6 percent year on year. The healthcare business, led by Fun and Health and Sl...
Shinnihonseiyaku Boosts Profit and Dividend Despite Margin Pressure
Aug 7, 2026
Shinnihonseiyaku reported consolidated net sales of ¥32,153 million for the nine months ended June 30, 2026, up 4.6% year on year, while operating and ordinary profits slipped modestly. Despite this margin pressure, profit attributable to own...
Shinnihonseiyaku Balances Modest Sales Growth with Heavy Investment in Star Brands
May 13, 2026
Shinnihonseiyaku reported first-half net sales of ¥20,517 million, up 1.2% year on year, driven by strong mail-order and e-commerce performance and a subscriber base that expanded by approximately 21,000, while cosmetics remained resilient de...
Shinnihonseiyaku Lifts Earnings, Keeps Forecast and Plans Higher Dividend
May 13, 2026
Shinnihonseiyaku reported semiannual consolidated net sales of ¥20.52 billion for the six months ended March 31, 2026, a modest 1.2% increase year on year, while operating and ordinary profit declined amid higher costs or investment pressures...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.